News for Lantern Pharma Inc. (LTRN)

Operator: Good morning, and welcome to our First Quarter 2025 Earnings Call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode.

The following slide deck was published by Lantern Pharma Inc.

Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ETCompany ParticipantsPanna Sharma - President & CEODavid...

Lantern Pharma (LTRN) achieved substantial progress in its AI-driven drug development pipeline during Q1 2025. Completion of LP-184 Phase 1a clinical tr

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence (AI) and machine learn

Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platfor

Lantern Pharma, trading under the ticker LTRN, has received approval from the U.S. Food and Drug Administration to amend its Investigational New Drug (IND) appl

Lantern Pharma, with the ticker LTRN, has successfully secured FDA approval for their investigational new drug application. This clearance allows them to procee

\n Lantern Pharma Inc. (LTRN) receives FDA clearance for an Investigational New Drug (IND) application for LP-184 in Triple Negative Breast Cancer (TNBC).

\nLantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platfor

Discover Lantern Pharma's transformative 2024 journey in precision oncology with AI breakthroughs, global trial expansions, and key clinical milestones for...

Cash Position: Approximately $24 million in cash, cash equivalents, and marketable securities as of December 31, 2024.Clinical Trials: Significant progress in

The artificial intelligence community is raving over a new reasoning model that has surprised even Silicon Valley.

We recently published a list of Complete List of All AI Companies Under $2 Billion Market Cap. In this article, we are going to take a look at where Lantern Pharma Inc.

It's clear that AI holds immense promise but it comes with significant risks.

**media[509218]**

Should original content contributors be paid every time large language models use their work? OpenAI CEO Sam Altman believes they should, much like Name, Image, and Likeness (NIL) deals for college athletes...

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, toda

We recently compiled a list of the 15 AI News Updates That Broke The Internet. In this article, we are going to take a look at where Lantern Pharma Inc.